Hope thrives in the desert
/images/waysGive_tb2.jpg

Ways to Give

We are a nonprofit organization which means we need your help! Leave a lasting legacy for future generations:
Make a tax-deductible donation
Volunteer

NVCI Stories

Cancer has touched the lives of many. Read the stories of individuals who chose treatment and services from us:

Learn About Our Sponsors

NVCI donors, individuals and corporations, are generous to the Institute and have unique, personal stories to tell. Read the stories of these individuals and companies who are grateful that NVCI is here for them and so many others:

State-of-the-Art

Our modern facilities, cutting-edge research, and caring staff make NVCI the only comprehensive cancer center for the state of Nevada. Learn more about what makes us different.

Internship Programs

Internship Programs

NVCI can play an important role in the lives of students by offering a meaningful opportunity to experience many exciting aspects of a career in healthcare. Learn more

Clinical Trials Update

Nevada Cancer Institute is committed to bringing innovative cancer therapy options to all cancer patients in Nevada.

Selected Trials

Advanced Malignancies
Phase I | Download criteria
Peripheral T-cell Lymphoma
Phase II | Download criteria
Advanced or Metastatic Pancreatic Cancer
Phase II | Download criteria

More Clinical Trials


NVCI Tumor Boards

Monthly tumor boards are held for presentation of the current state of a particular cancer and are followed by a presentation of interesting and/or difficult cases. Learn more

Contact Us
Please contact us with any questions or comments.
(702) 822-LIFE

(866) 621-NVCI

FightHere.org

NVCI Faculty Published in Prominent Medical Journals

Several Nevada Cancer Institute faculty members have been published in some important medical journals. Wolfram Samlowski, M.D., head of the Section of Melanoma, Renal Cancer and Immunotherapy; Bryan Wong, M.D., Ph.D., assistant member, Department of Hematological Malignancies; and Nicholas Vogelzang, M.D., director and executive vice president for Academic Affairs, wrote an editorial which was published in the British Journal of Urology International. The editorial is titled, “Management of renal cancer in the tyrosine kinase inhibitor era: a view from 3 years on.”

The editorial pointed out that there has been a dramatic increase in the treatment options for patients with metastatic renal cancer. In addition to the cytokines interferon and interleukin 2, recently approved agents include sorafenib, sunitinib, temsirolimus and bevacizumab. A large number of agents that are likely to have clinical activity are currently in the development ‘pipeline’. The editorial was an overview of recent developments that identified advances likely to influence treatment decisions.

read more »

Latest News

Physicians Practice and Nevada Cancer Institute Partner to Improve Patient Care

Read more

Clark County Board of County Commissioners approves Nevada Cancer Institute to provide Radiation Oncology services for University Medical Center

Read more

Four Seasons & Nevada Cancer Institute Make Strides In The Fight Against Cancer With 9th Annual Halloween Run For Cancer Research, Oct. 25

Read more

Maps & Directions

To visit our state-of-the-art, flagship facility click here.

Outreach & Education offices:

Las Vegas | Sparks | Elko | Fallon